Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

185.58 -2.51 (-1.33%)
Official Closing Price Updated: 7:00 PM EDT, May 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
79 80 Next >
Investors Are Flocking to These 3 Vanguard Sector ETFs. Should You Buy Them Too?
Via The Motley Fool
Topics ETFs Economy Government
Exposures Economy Political Tariff
Retired At 58, He 'Spent Between $1M-$2M On Stocks' – Investor Who Built An 8% Yield Portfolio And Lives Off Dividends Shares Top Holdings
Via Benzinga
From Rookie Mistakes To $10K/Year In Dividends – Military Veteran Who 'Made A Few Great Plays' Shares His 10 Biggest Bets
Via Benzinga
2 Dividend Stocks Defying the Market Dip to Buy for a Lifetime of Passive Income
Via The Motley Fool
Stocks Going Ex Dividend In April 2025
The following is a short list of some of the many stocks going ex-dividend during the next month, which can be helpful for traders and investors interested in the stock trading technique known as... 
Via Talk Markets
Topics Stocks / Equities
What's going on in today's session: S&P500 movers
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday. 
Via Chartmill
Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside
Avalo Therapeutics' AVTX-009 is advancing in hidradenitis suppurativa, with Phase 2 data expected in 2026. Stifel initiates coverage with a $36 price target. 
Via Benzinga
Tuesday's session: top gainers and losers in the S&P500 index
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday. 
Via Chartmill
Smart Money Is Betting Big In ABBV Options
Via Benzinga
3 Healthcare Stocks in the Doghouse
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Moderna (NASDAQ:MRNA) and the best and worst... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Regencell, GlucoTrack, TC Biopharm, AbbVie, Actinium: 5 Health Care Stocks That Lit Up Retail Discussions Last Week
Investors reacted to insider buying, clinical trial updates, and strategic business shifts that happened in the week ended March 21, 2025. 
Via Stocktwits
AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
Abbvie made an all-time high after announcing an agreement that puts it in the weight loss market; but that just continues a general uptrend in ABBV stock 
Via MarketBeat
Is AbbVie Gaining or Losing Market Support?
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
AbbVie Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Here's How Many Shares of AbbVie You Need to Own to Get $1,000 in Yearly Dividends
Via The Motley Fool
Elliott Wave Technical Analysis: AbbVie Inc. - Wednesday, March 19
A pullback in Wave {iv} is expected before resuming the overall trend. 
Via Talk Markets
Topics Stocks / Equities
3 Dividend Stocks to Buy for Reliable Passive Income
Via The Motley Fool
AbbVie's Elahere Cuts Death Risk By 32%, Shows Consistent Survival Benefit In Long-Term Analysis For Certain Ovarian Cancer Patients
AbbVie's Elahere maintains strong efficacy in the Phase 3 MIRASOL trial for ovarian cancer, with durable survival benefits and consistent safety data. 
Via Benzinga
1 No-Brainer High-Yield Dividend ETF to Buy During the Stock Market Correction
Via The Motley Fool
Topics ETFs
Generate Passive Income From This Low-Cost Vanguard ETF That Is Crushing the S&P 500 in 2025
Via The Motley Fool
Topics ETFs Stocks
Exposures US Equities
3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
Via The Motley Fool
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
The company is looking to test a combination of the drug it acquired from Carmot Therapeutics and a amylin-based drug. 
Via Investor's Business Daily
Worried About a Market Meltdown? 2 Dividend Stocks to Own Forever.
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Vanguard High Dividend Yield ETF vs Vanguard Dividend Appreciation ETF: Which Is Best for You?
Vanguard has some excellent dividend ETFs, but they are right for different investors. 
Via The Motley Fool
Topics ETFs
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas
There's a lot going on for investors. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
79 80 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.